menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Where are the New Targets in Severe Asthma? Looking Upstream in the Inflammatory Cascade

Stay up to date on the latest potential targets for treatment and novel therapies that may improve outcomes for patients with severe asthma. 

Live Broadcast
1.00 available credits
Information
November 02, 2021
08:00 PM - 09:00 PM EDT
Online
ReachMD Healthcare Image
Choose a format
Details
Presenters
Comments
  • Overview

    In this session, National Jewish Health faculty experts will discuss a new paradigm of severe asthma pathophysiology and potential treatment targets that may impact patients with non-allergic and non-eosinophilic as well as eosinophilic severe asthma. This session will explore new understanding of the immunology of severe asthma, new potential targets for treatment, and emerging data on novel therapies that may improve outcomes for your patients with severe asthma. 

  • Disclosure of Conflicts of Interest

    In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

    Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.

    All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Continuing Education.

    Faculty Disclosures:

    Michael Wechsler, MD, MMSc discloses that he is a consultant and investigator for AstraZeneca and a consultant for Amgen.

    Eileen Wang, MD, MPH discloses that she is a consultant for AstraZeneca.

    Planner and Reviewer Disclosures:

    Meghan Brenner, MA has no relevant financial relationships to disclose
    Marye Caslavka, M.A.Ed has no relevant financial relationships to disclose
    Anthony Gerber, MD has no relevant financial relationships to disclose
    Andrea Harshman, MHA, CHCP, CMP-HC has no relevant financial relationships to disclose
    Harold S. Nelson, MD discloses he is a consultant for ALK and is on the data safety monitoring board for AstraZeneca.

  • Target Audience

    Pulmonologists, Allergists, and other health care providers who treat patients with severe asthma.

  • Learning Objectives

    Upon completion of this activity, the participant will be better able to:

    1. Define the epithelial alarmins and their pivotal role in inflammation in asthma.
    2. Describe how the epithelial alarmins impact both T2 and non-T2 downstream inflammation in asthma.
    3. Explain how therapies, such as anti-TSLP, would be expected to modulate airway inflammation in patients with either a T2-high or T2-low phenotype.
    4. Evaluate the results of clinical trials of novel therapies that target the epithelial alarmins.
  • Accreditation and Credit Designation Statements

    National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    National Jewish Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclaimer

    Disclosure of Unlabeled Use
    The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

    No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.

    Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.

    Disclaimer
    National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.

    By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.

    Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.

    Privacy Policy
    The Office of Professional Education of National Jewish Health respects and values your privacy and the confidentiality of the information you choose to share with us. We are committed to protection of this information and will assure your privacy when participating in our Internet Continuing Medical Education (CME). 

    We do not collect any personal information about a visit unless that information is provided voluntarily. We may collect aggregate information on web pages visited in order to assess and improve the content of our Internet CME programming.

    If you decide to register for an Internet CME program, we will collect personal information that you voluntarily share with us. We will only use this information to notify you of future National Jewish Health CME activities.
    https://www.nationaljewish.org/education-training/pro-ed/privacy-policy-and-practices

  • Provider(s)/Educational Partner(s)

    Provided by National Jewish Health. 

  • Commercial Support

    This educational activity is supported by an educational grant from AstraZeneca Pharmaceuticals. 

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Details
Presenters
Comments
Recommended
  • Overview

    In this session, National Jewish Health faculty experts will discuss a new paradigm of severe asthma pathophysiology and potential treatment targets that may impact patients with non-allergic and non-eosinophilic as well as eosinophilic severe asthma. This session will explore new understanding of the immunology of severe asthma, new potential targets for treatment, and emerging data on novel therapies that may improve outcomes for your patients with severe asthma. 

  • Disclosure of Conflicts of Interest

    In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

    Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.

    All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Continuing Education.

    Faculty Disclosures:

    Michael Wechsler, MD, MMSc discloses that he is a consultant and investigator for AstraZeneca and a consultant for Amgen.

    Eileen Wang, MD, MPH discloses that she is a consultant for AstraZeneca.

    Planner and Reviewer Disclosures:

    Meghan Brenner, MA has no relevant financial relationships to disclose
    Marye Caslavka, M.A.Ed has no relevant financial relationships to disclose
    Anthony Gerber, MD has no relevant financial relationships to disclose
    Andrea Harshman, MHA, CHCP, CMP-HC has no relevant financial relationships to disclose
    Harold S. Nelson, MD discloses he is a consultant for ALK and is on the data safety monitoring board for AstraZeneca.

  • Target Audience

    Pulmonologists, Allergists, and other health care providers who treat patients with severe asthma.

  • Learning Objectives

    Upon completion of this activity, the participant will be better able to:

    1. Define the epithelial alarmins and their pivotal role in inflammation in asthma.
    2. Describe how the epithelial alarmins impact both T2 and non-T2 downstream inflammation in asthma.
    3. Explain how therapies, such as anti-TSLP, would be expected to modulate airway inflammation in patients with either a T2-high or T2-low phenotype.
    4. Evaluate the results of clinical trials of novel therapies that target the epithelial alarmins.
  • Accreditation and Credit Designation Statements

    National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    National Jewish Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclaimer

    Disclosure of Unlabeled Use
    The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

    No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.

    Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.

    Disclaimer
    National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.

    By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.

    Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.

    Privacy Policy
    The Office of Professional Education of National Jewish Health respects and values your privacy and the confidentiality of the information you choose to share with us. We are committed to protection of this information and will assure your privacy when participating in our Internet Continuing Medical Education (CME). 

    We do not collect any personal information about a visit unless that information is provided voluntarily. We may collect aggregate information on web pages visited in order to assess and improve the content of our Internet CME programming.

    If you decide to register for an Internet CME program, we will collect personal information that you voluntarily share with us. We will only use this information to notify you of future National Jewish Health CME activities.
    https://www.nationaljewish.org/education-training/pro-ed/privacy-policy-and-practices

  • Provider(s)/Educational Partner(s)

    Provided by National Jewish Health. 

  • Commercial Support

    This educational activity is supported by an educational grant from AstraZeneca Pharmaceuticals. 

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Schedule27 Nov 2021
Webpack App